Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: Mel Spivak who wrote (268)	3/10/2000 9:06:00 AM
From: BRAVEHEART	Read Replies (5) \| Respond to of 423

Hi Tuck, While I like QTRN's prospects keep an eye on the MACD histogram. QTRN was @ around $19 a couple other times in the last several months. However the stock gapped down big this time & the Histogram still shows considerable weakness. I would act in a day and then wait. I expect to see new lows based on technicals. This could be a bottom but don't try & catch a falling knife. Especially from the second floor. Panic has a motive "yet" in this issue. It's one year low is $16. Analists are likely to start downgrading QTRN. It likely will trade down through earnings. Especially since they stated these moves will affect the next two quarters. It should be interesting and likely it will provide an opportunity somewhere sometime. However the one aspect that threw me was the stmnt about how Big Pharma's cutting back has hurt their bottom line. Not good Long Term. All this money flowing into biotech "today" will definately translate into more clinicals later especially with the explosion in Genomics ( GLGC etc ) and the new mouses { I know meece ( MEDX etc )} QTRN should have some upside eventially assuming they are managed towards the future and not treated like a cow. The links you provided says there is a future with QTRN. Looking for an Earnings related bottom line. Do ya have a date on this??? Mel I targeted MEDX back when it was trading at $3. Like GLGC there is no way I thought it would hit this level so soon. Yes MEDX is a biotech with a product being realized both today and in the future. That darn Mouse... MEDX should be a decent hold long term especially after it splits. Which it should do after it is through raising cash through secondaries. The only issue is competing mouses. Watch & understand this technology & the patent issues. For now it is a powerhouse. Right now it looks like MEDX is seeking both a range and fair value. I like it a lot more than GLGC. PDLI is another one of my faviorites... It's just that w/o any way to measure value it is hard to predict if MEDX will correct some or not. My gut feel is it has ample resistance around $100 and loses interest between $180 & $200. Hence I may bite if it hit's $100 to $120... BEST WISHES Jeffrey